Human Disease Model Report: cachexia, yki-induced ISC tumor model

General Information

Name

cachexia, yki-induced ISC tumor model

FlyBase ID

FBhh0001115

Disease Ontology Term

cancer

Parent Disease

OMIM

Overview

This report describes a tumor model using an activated form of Dmel\yki expressed in adult intestinal stem cells (ISC) and the use of this model to investigate the phenomenon of cachexia. Dmel\yki is orthologous to human YAP1 and is a core component of the Hippo Signaling Pathway (FBgg0000913); see the human disease model report 'cancer, multiple, Hippo signaling pathway' (FBhh0000764).

When an activated form of Dmel\yki is specifically expressed in adult intestinal stem cells of the midgut, sequential steps of tumor development are observed, each lasting approximately 2 days: proliferation state; tumorigenesis state, during which tumors expand to the whole midgut; ascites state, during which the abdomen expands and muscle dysfunction is observed; wasting or bloating state, with further abdomen expansion, severe TAG decrease, carbohydrate increase, and muscle dysfunction.

MEK/ERK (MAPK/ERK) signaling is observed to increase during this progression, in both tumors and non-tumorous host tissues. Tumor MEK/ERK activation is required for tumor growth. Non-autonomous activation of MEK/ERK in host tissues results in muscle wasting and lipid loss. This system has allowed characterization and comparison of molecular mechanisms involved in ISC tumor development and resulting changes in non-tumorous tissues. In an assessment of the contribution of various candidate ligand genes, it was determined that Pvf1 and its receptor Pvr play a key role in this process. One of the conclusions of these studies is that Pvf1 and ImpL2 are independent regulators of the non-autonomous tissue wasting observed with yki-induced ISC tumors; see the human disease model report 'cachexia, IGFBP-related' (FBhh0000535).

Several MEK pharmaceutical inhibitors were shown to ameliorate the wasting phenotypes.

The Warburg effect (preferential use of aerobic glycolysis by cancer cells) may be one of the contributing factors in the development of cachexia. See human disease model reports 'cancer, aerobic glycolysis (Warburg effect), larval growth ' (FBhh0000502) and 'cancer, epithelial, glycolytic tumor model' (FBhh0000959).

[updated Apr. 2021 by FlyBase; FBrf0222196]

Disease Summary Information

Disease Summary: cachexia, yki-induced ISC tumor model

OMIM report

Human gene(s) implicated

Symptoms and phenotype

Cachexia is characterized by a dramatic loss of skeletal muscle mass and adipose tissue, resulting in substantial weight loss. It is also known as "wasting syndrome", causing disproportionate muscle wasting, weakness, fatigue, and loss of appetite in affected individuals. Cachexia occurs in many cancers, usually at the advanced stages of disease. [ http://www.news-medical.net/health/Cachexia-Wasting-Syndrome-.aspx ] [ https://www.cancer.gov/about-cancer/treatment/research/cachexia ]

(FlyBase Curators, 2013-)

Genetics

Cellular phenotype and pathology

Molecular information

External links

KEGG Disease Pathways: Pathways in Cancer
NCBI MedGen: Cachexia

Disease synonyms

cachexia, MAPK/ERK signaling model

cachexia, MEK/ERK signaling model

wasting syndrome

Related Diseases

Related human health report(s)

cachexia, IGFBP-related

cachexia, yki-induced eye tumor model

cancer, aerobic glycolysis (Warburg effect), larval growth model

cancer, epithelial, glycolytic tumor model

cancer, intestinal stem cell models

cancer, multiple, Hippo signaling pathway

Ortholog Information

Human gene(s) in FlyBase

Other mammalian ortholog(s) used

D. melanogaster Gene Information (1)

Dmel\yki

Gene Snapshot

yorkie (yki) encodes a transcriptional co-activator protein that is negatively regulated by Hippo signaling, which promotes its cytoplasmic localization. It functions together with DNA binding proteins, such as the product of sd, to activate transcription of a wide range of downstream targets, including genes that promote growth. [Date last reviewed: 2019-03-21]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

SWH-C

Comments on ortholog(s)

Moderate-scoring ortholog of human YAP1; lower-scoring ortholog of WWTR1 (1 Drosophila to 2 human). Dmel\yki shares 31% identity and 45% similarity with YAP1; it shares 25% identity and 34% similarity with WWTR1.

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Other Genes Used: Viral, Bacterial, Synthetic (0)

Summary of Physical Interactions (79 groups)

yki

RNA-RNA

Interacting group

Assay

References

yki - mir-7

luminiscence technology

(Yu et al., 2020)

yki - mir-8

fluorescence technology

(Sander et al., 2018)

RNA-protein

Interacting group

Assay

References

yki - Rox8

anti tag coimmunoprecipitation, quantitative reverse transcription pcr

(Guo et al., 2020)

protein-protein

Interacting group

Assay

References

yki - 14-3-3ε

anti tag coimmunoprecipitation, anti tag western blot, peptide massfingerprinting, protein complementation assay

(Srivastava et al., 2021, Wang et al., 2016, Hu et al., 2014, Kwon et al., 2013, Wehr et al., 2013, Ren et al., 2010, Oh and Irvine, 2008)

yki - 14-3-3ζ

anti tag coimmunoprecipitation, anti tag western blot, western blot, peptide massfingerprinting

(Srivastava et al., 2021, Wang et al., 2016, Hu et al., 2014, Kwon et al., 2013, Ren et al., 2010, Oh and Irvine, 2008, Dong et al., 2007)

yki - Ack

anti tag coimmunoprecipitation, western blot, peptide massfingerprinting, anti tag western blot, pull down

(Hu et al., 2016, Kwon et al., 2013, Schoenherr et al., 2012)

yki - Akt

enzymatic study, western blot

(Li et al., 2022)

yki - Atpα

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - Bap111

anti bait coimmunoprecipitation, peptide massfingerprinting

(Oh et al., 2013)

yki - bon

pull down, Identification by mass spectrometry, anti tag coimmunoprecipitation, anti tag western blot

(Zhao et al., 2023)

yki - brm

anti bait coimmunoprecipitation, peptide massfingerprinting, anti tag coimmunoprecipitation, anti tag western blot

(Zhu et al., 2015, Jin et al., 2013, Oh et al., 2013)

yki - CalpA

anti tag coimmunoprecipitation, Identification by mass spectrometry, anti tag western blot

(Zhai et al., 2024)

yki - CalpB

anti tag coimmunoprecipitation, anti tag western blot

(Zhai et al., 2024)

yki - caz

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - cbt

anti tag coimmunoprecipitation, anti tag western blot, western blot

(Srivastava et al., 2021, Ruiz-Romero et al., 2015)

yki - Cdk7

enzymatic study, western blot

(Cho et al., 2020)

yki - CG2186

anti tag coimmunoprecipitation, anti tag western blot, peptide massfingerprinting

(Kwon et al., 2013, Kwon et al., 2013)

yki - CG9581

anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot

(Kwon et al., 2013, Kwon et al., 2013)

yki - CG15117

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - CG31705

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - ci

anti tag coimmunoprecipitation, anti tag western blot

(Li et al., 2015)

yki - Cpsf5

anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot

(Kwon et al., 2013, Kwon et al., 2013)

yki - Cpsf6

anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot

(Kwon et al., 2013, Kwon et al., 2013)

yki - DCAF12

anti tag coimmunoprecipitation, anti tag western blot

(Cho et al., 2020)

yki - dsh

anti tag coimmunoprecipitation, tag visualisation

(Varelas et al., 2010)

yki - EcR

coimmunoprecipitation, western blot

(Zhang et al., 2015)

yki - ed

anti tag coimmunoprecipitation, anti tag western blot

(Yue et al., 2012)

yki - EMC1

anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot

(Kwon et al., 2013, Kwon et al., 2013)

yki - ex

anti bait coimmunoprecipitation, western blot, anti tag coimmunoprecipitation, anti tag western blot, Identification by mass spectrometry, pull down, peptide massfingerprinting

(Wang et al., 2022, Srivastava et al., 2021, Hu et al., 2016, Kwon et al., 2013, Badouel et al., 2009, Oh et al., 2009)

yki - foxo

anti bait coimmunoprecipitation, western blot, anti tag coimmunoprecipitation, anti tag western blot, pull down

(Sun et al., 2024)

yki - Fs(2)Ket

pull down, peptide massfingerprinting

(Wang et al., 2016)

yki - Helz

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - Hipk

enzymatic study, autoradiography, anti tag coimmunoprecipitation, anti tag western blot

(Steinmetz et al., 2021, Chen and Verheyen, 2012)

yki - hpo

anti tag coimmunoprecipitation, anti tag western blot, peptide massfingerprinting

(Srivastava et al., 2021, Dent et al., 2015, Oh et al., 2009)

yki - Hsc70-3

proximity ligation assay, fluorescence microscopy, anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot

(Yang et al., 2022, Kwon et al., 2013, Kwon et al., 2013)

yki - hth

anti tag coimmunoprecipitation, anti tag western blot

(Srivastava et al., 2021, Peng et al., 2009)

yki - Inos

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - Ist1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - Kap-α1

anti tag coimmunoprecipitation, anti tag western blot, pull down, peptide massfingerprinting

(Wang et al., 2016)

yki - Lasp

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - Leash

anti tag coimmunoprecipitation, anti tag western blot, peptide massfingerprinting

(Shen et al., 2018, Kwon et al., 2013, Kwon et al., 2013, Kwon et al., 2013)

yki - Mad

anti tag coimmunoprecipitation, anti tag western blot, western blot

(Srivastava et al., 2021, Oh and Irvine, 2011, Alarcón et al., 2009)

yki - mask

anti tag coimmunoprecipitation, anti tag western blot

(Sansores-Garcia et al., 2013, Sidor et al., 2013)

yki - MED1

anti bait coimmunoprecipitation, peptide massfingerprinting

(Oh et al., 2013)

yki - MED15

anti bait coimmunoprecipitation, peptide massfingerprinting

(Oh et al., 2013)

yki - MED19

anti bait coimmunoprecipitation, peptide massfingerprinting

(Oh et al., 2013)

yki - MED23

anti bait coimmunoprecipitation, peptide massfingerprinting

(Oh et al., 2013)

yki - MED31

anti bait coimmunoprecipitation, peptide massfingerprinting

(Oh et al., 2013)

yki - mesh

anti tag coimmunoprecipitation, anti tag western blot

(Chen et al., 2020)

yki - Mitf

anti tag coimmunoprecipitation, anti tag western blot

(Zhang et al., 2024)

yki - mop

pull down, peptide massfingerprinting, tandem affinity purification, Identification by mass spectrometry, anti tag coimmunoprecipitation, anti tag western blot

(Hu et al., 2016, Kwon et al., 2013, Gilbert et al., 2011)

yki - mor

anti tag coimmunoprecipitation, anti tag western blot, pull down, anti bait coimmunoprecipitation, peptide massfingerprinting, western blot

(Srivastava et al., 2021, Oh et al., 2013)

yki - Ncoa6

pull down, western blot, anti tag coimmunoprecipitation, anti tag western blot

(Srivastava et al., 2021, Oh et al., 2014, Qing et al., 2014)

yki - nerfin-1

anti tag coimmunoprecipitation, peptide massfingerprinting, experimental knowledge based, anti tag western blot

(Guo et al., 2019, Rhee et al., 2014)

yki - osa

anti bait coimmunoprecipitation, peptide massfingerprinting

(Jin et al., 2013)

yki - ovo

anti tag coimmunoprecipitation, anti tag western blot

(Bohère et al., 2018)

yki - p53

anti tag coimmunoprecipitation, anti tag western blot

(Di Cara et al., 2015)

yki - Pen

pull down, peptide massfingerprinting

(Wang et al., 2016)

yki - Polr2A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - Prp4k

enzymatic study, autoradiography

(Cho et al., 2018)

yki - Ptp61F

anti tag coimmunoprecipitation, western blot, anti tag western blot

(Liu et al., 2022)

yki - Rae1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - Rbf

anti tag coimmunoprecipitation, anti tag western blot, anti bait coimmunoprecipitation

(Rader et al., 2023)

yki - RhoGAP15B

anti tag coimmunoprecipitation, peptide massfingerprinting

(Kwon et al., 2013)

yki - RpS15Ab

experimental knowledge based

(Guruharsha et al., 2011)

yki - sd

anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot, pull down, autoradiography, two hybrid, surface plasmon resonance, predetermined participant, anti bait coimmunoprecipitation, fluorescent resonance energy transfer, western blot

(Sun et al., 2024, Zhai et al., 2024, Mesrouze et al., 2022, Srivastava et al., 2021, Bajpai et al., 2020, Mesrouze et al., 2020, Guo et al., 2019, Cho et al., 2018, Zhang et al., 2017, Li et al., 2015, Ikmi et al., 2014, Cagliero et al., 2013, Guo et al., 2013, Kwon et al., 2013, Oh et al., 2013, Goulev et al., 2008, Wu et al., 2008, Zhang et al., 2008)

yki - Sec31

anti tag coimmunoprecipitation, anti tag western blot, peptide massfingerprinting

(Kwon et al., 2013, Kwon et al., 2013)

yki - Ssk

anti tag coimmunoprecipitation, anti tag western blot

(Chen et al., 2020)

yki - Strn-Mlck

anti tag coimmunoprecipitation, anti tag western blot

(Xu et al., 2018)

yki - tai

coimmunoprecipitation, anti tag western blot, anti tag coimmunoprecipitation, peptide massfingerprinting

(Zhang et al., 2015, Kwon et al., 2013)

yki - Tgi

molecular sieving, molecular weight, isothermal titration calorimetry, predetermined participant, anti tag coimmunoprecipitation, anti tag western blot, pull down, Identification by mass spectrometry, peptide massfingerprinting, two hybrid, nuclear magnetic resonance

(Srivastava et al., 2021, Vissers et al., 2020, Nyarko, 2018, Guo et al., 2013, Koontz et al., 2013, Kwon et al., 2013)

yki - Trl

anti bait coimmunoprecipitation, peptide massfingerprinting, pull down, anti tag western blot, anti tag coimmunoprecipitation, western blot

(Srivastava et al., 2021, Oh et al., 2013)

yki - trr

pull down, western blot

(Oh et al., 2014)

yki - tsr

proximity ligation assay, fluorescence microscopy, anti tag coimmunoprecipitation, western blot, bimolecular fluorescence complementation

(Skouloudaki et al., 2019)

yki - Usp7

pull down, western blot, anti tag coimmunoprecipitation, anti tag western blot

(Sun et al., 2024, Sun et al., 2019)

yki - Usp10

anti tag coimmunoprecipitation, anti tag western blot

(Gao et al., 2019)

yki - vg

anti tag coimmunoprecipitation, anti tag western blot

(Li et al., 2015)

yki - Wbp2

pull down, peptide massfingerprinting, anti tag coimmunoprecipitation, anti tag western blot

(Srivastava et al., 2021, Hu et al., 2016, Kwon et al., 2013, Zhang et al., 2011)

yki - wts

enzymatic study, autoradiography, pull down, peptide massfingerprinting, anti tag coimmunoprecipitation, anti tag western blot, western blot, two hybrid

(Zhao et al., 2023, Srivastava et al., 2021, Hao et al., 2020, Hu et al., 2016, Hu et al., 2014, Kwon et al., 2013, Sansores-Garcia et al., 2013, Badouel et al., 2009, Oh et al., 2009, Zhang et al., 2009, Wu et al., 2008, Dong et al., 2007, Huang et al., 2005)

Alleles Reported to Model Human Disease (Disease Ontology) (23 alleles)

yki

Models Based on Experimental Evidence ( 14 )

Allele

Disease

Evidence

References

yki^UAS.cHa

model of cancer

CEA

(Liu et al., 2022, Yang et al., 2022, Nagarkar et al., 2020, Ziosi et al., 2010)

CEA with pnut^GD1512

(Gerlach et al., 2018)

model of neurodegenerative disease

CEA

(Napoletano et al., 2011)

model of carcinoma

CEA with l(2)gl⁴

(Singh et al., 2022)

CEA

(Groth et al., 2020)

model of heart disease

CEA

(Karekar et al., 2021)

yki^{S168A.UAS.cUa}

model of cancer

CEA

(Jang et al., 2017)

yki^{S168A.UAS.EGFP,Tag:HA}

model of cancer

CEA

(Yeom et al., 2021, Yeom et al., 2020, Bunker et al., 2015)

yki^{UAS.cOa.Tag:V5}

model of carcinoma

CEA with l(2)gl⁴

(Enzo et al., 2015)

yki^{S168A.UAS.Tag:V5}

model of cancer

CEA

(Hodgson et al., 2021, Santabárbara-Ruiz and Léopold, 2021)

model of ovarian cancer

CEA

(Hall et al., 2010)

yki^{S111A.S168A.S250A.UAS.Tag:V5}

model of intestinal cancer

CEA

(Xu et al., 2024, Pranoto et al., 2023, Saavedra et al., 2023, Wang et al., 2023, Kim et al., 2022, Bajpai et al., 2020)

model of cancer

CEA

(Pranoto and Kwon, 2024, Xu et al., 2023, Chen et al., 2022, Ding et al., 2021, Lee et al., 2021)

CEA with hop^Tum.UAS

(Ding et al., 2021)

model of neurodegenerative disease

CEA

(Napoletano et al., 2011)

model of carcinoma

CEA

(Singh et al., 2022)

CEA with scrib^HMJ21977

(Snigdha et al., 2021)

model of nephrolithiasis

CEA

(Xu et al., 2024)

yki^UAS.cUa

model of cancer

CEA with RhoBTB^HMC03199

(Nguyen et al., 2020)

CEA with RhoBTB^VSH330130

(Nguyen et al., 2020)

CEA with Lkb1^KK108675

(Nguyen et al., 2020)

CEA with Lkb1^HMS01351

(Nguyen et al., 2020)

CEA with Lkb1^GL00019

(Nguyen et al., 2020)

CEA with Lkb1^VSH330167

(Nguyen et al., 2020)

CEA

(Guo et al., 2020)

yki^3SA.UAS.cUa

model of cancer

CEA

(Lodge et al., 2021)

yki^{UAS.UTR.Tag:MYC}

model of cancer

CEA

(Guo et al., 2020)

yki^{UAS.UTR-M1.Tag:MYC}

model of cancer

CEA

(Guo et al., 2020)

yki^{UAS.UTR-M2.Tag:MYC}

model of cancer

CEA

(Guo et al., 2020)

yki^{3SA.lexAop.Tag:V5}

model of cancer

CEA

(Lee et al., 2021)

yki^{3SA.lexAop.Tag:Myr(Unk),GFP}

model of cancer

CEA

(Chen et al., 2022)

yki^{3SA.lexAop.sfGFP}

model of intestinal cancer

CEA

(Xu et al., 2024, Saavedra et al., 2023)

Modifiers Based on Experimental Evidence ( 19 )

Allele

Disease

Interaction

References

yki^RNAi.N.UAS

ameliorates cancer

modeled by Ras85D^V12.UAS

(Waghmare et al., 2024)

exacerbates Alzheimer's disease 1

modeled by Hsap\APP^{Aβ42.UAS.cUa}

(Irwin et al., 2020)

yki^RNAi.C.UAS

ameliorates cancer

modeled by Ras85D^V12.UAS

(Waghmare et al., 2024)

yki^UAS.cHa

ameliorates neurodegenerative disease

modeled by ft⁸

(Napoletano et al., 2011)

modeled by Zzzz\CAG^{127Q.UAS.Tag:HA}

(Dubey and Tapadia, 2018)

modeled by Hsap\HTT^Q93.ex1.UAS

(Dubey and Tapadia, 2018)

model of cancer

is exacerbated by sd^UAS.cSa

(Ziosi et al., 2010)

is ameliorated by Myc^GD1419

(Ziosi et al., 2010)

is ameliorated by Xbp1^UAS.s.Tag:V5

(Yang et al., 2022)

is ameliorated by Hsc70-3^{UAS.ORF.Tag:HA}

(Yang et al., 2022)

is ameliorated by Ire1^UAS.Tag:V5

(Yang et al., 2022)

model of carcinoma

is exacerbated by Cdk9^UAS.ORF

(Nagarkar et al., 2020)

is exacerbated by Hexim^KK104531

(Nagarkar et al., 2020)

is exacerbated by NELF-B^KK100078

(Nagarkar et al., 2020)

is exacerbated by Nelf-A^KK101005

(Nagarkar et al., 2020)

is exacerbated by bin3^KK106875

(Nagarkar et al., 2020)

yki^B5

ameliorates neurodegenerative disease

modeled by ft⁸

(Napoletano et al., 2011)

ameliorates cancer

modeled by scrib¹

(Bunker et al., 2015)

modeled by Ras85D^V12.UAS, Rox8^GD11645

(Guo et al., 2020)

ameliorates brain cancer

modeled by l(3)mbt^GM76

(Richter et al., 2011)

yki^NIG.4005R

ameliorates cancer

modeled by shot^GL01286

(Jain et al., 2019)

yki^HMS00041

ameliorates cancer

modeled by dlg1^GD4689, Ras85D^V12.UAS

(Katheder et al., 2017)

ameliorates high grade glioma

modeled by Pten^{RNAi.Exel.UAS}, Ras85D^V12.cUa.UAS

(Gangwani et al., 2020)

modeled by Pi3K92E^{UAS.Tag:MYC,Tag:PM(hKRAS)}, btl::Egfr^λ.UAS

(Vigneswaran et al., 2021)

DOES NOT ameliorate cancer

modeled by Hipk^UAS.Tag:HA

(Blaquiere et al., 2018)

yki^GD11187

ameliorates intestinal cancer

modeled by Ptp61F^HMS00421

(Liu et al., 2022)

ameliorates kidney disease

modeled by sdt^NIG.15342R

(Weide et al., 2017)

modeled by sdt^HMS01652

(Weide et al., 2017)

yki^KK109756

ameliorates colorectal cancer

modeled by SH3PX1^d1

(Zhang et al., 2019)

ameliorates high grade glioma

modeled by Pi3K92E^{UAS.Tag:MYC,Tag:PM(hKRAS)}, btl::Egfr^λ.UAS

(Vigneswaran et al., 2021)

yki^{S168A.UAS.cUa}

model of cancer

is ameliorated by lz^UAS.cBa

(Jang et al., 2017)

is exacerbated by trio^UAS.cUa

(Jang et al., 2017)

yki^{S168A.UAS.EGFP,Tag:HA}

model of cancer

is ameliorated by AlaRS^GD8009

(Yeom et al., 2020)

is exacerbated by ArgRS^GD14098

(Yeom et al., 2020)

is ameliorated by AsnRS^GD7064

(Yeom et al., 2020)

is ameliorated by AsnRS^KK100240

(Yeom et al., 2020)

is ameliorated by AspRS^GD1339

(Yeom et al., 2020)

is exacerbated by CysRS^GD13923

(Yeom et al., 2020)

is exacerbated by GlnRS^KK109443

(Yeom et al., 2020)

is exacerbated by GluProRS^GD11635

(Yeom et al., 2020)

is ameliorated by GlyRS^KK107421

(Yeom et al., 2020)

is exacerbated by HisRS^KK102374

(Yeom et al., 2020)

is exacerbated by LysRS^KK101852

(Yeom et al., 2020)

is exacerbated by SerRS-m^GD12798

(Yeom et al., 2020)

is exacerbated by ThrRS^GD1342

(Yeom et al., 2020)

is exacerbated by TyrRS^GD11353

(Yeom et al., 2020)

is ameliorated by ImpL2^GD6004

(Yeom et al., 2021)

is ameliorated by Ilp8^KK112161

(Yeom et al., 2021)

is ameliorated by Ilp8^MI00727

(Yeom et al., 2021)

is ameliorated by Lgr3^Δ50

(Yeom et al., 2021)

exacerbates cancer

modeled by Hipk^UAS.Tag:HA

(Blaquiere et al., 2018)

yki^{UAS.cOa.Tag:V5}

ameliorates Alzheimer's disease 1

modeled by Hsap\APP^{Aβ42.UAS.cUa}

(Irwin et al., 2020)

yki^{S111A.S168A.S250A.UAS.Tag:V5}

model of intestinal cancer

is ameliorated by Ilp2^UAS.cUa

(Wang et al., 2023)

is ameliorated by ImpL2^NIG.15009R

(Wang et al., 2023)

is ameliorated by mew^JF02694

(Bajpai et al., 2020)

is ameliorated by rhea^HM05161

(Bajpai et al., 2020)

is ameliorated by vg^TONDU.UAS

(Bajpai et al., 2020)

is ameliorated by whd^HMS00040

(Saavedra et al., 2023)

is ameliorated by ImpL2^HMC05809

(Pranoto et al., 2023)

is ameliorated by Mmp1^JF01336

(Pranoto et al., 2023)

is ameliorated by N^DN.UAS.cUa

(Pranoto et al., 2023)

is ameliorated by upd2^HMS00901

(Pranoto et al., 2023)

is ameliorated by upd2^HMS00948

(Pranoto et al., 2023)

is exacerbated by zfh2^EAB

(Pranoto et al., 2023)

is ameliorated by Pvf1^KK112211

(Xu et al., 2024)

model of cancer

is ameliorated by Akt^HMS00007

(Lee et al., 2021)

is ameliorated by foxo^TM.UAS

(Lee et al., 2021)

is ameliorated by pan^ΔN.UAS

(Lee et al., 2021)

is ameliorated by wg^HMS00794

(Lee et al., 2021)

is ameliorated by wg^JF01257

(Lee et al., 2021)

is ameliorated by ITP^GD3825

(Xu et al., 2023)

is ameliorated by ITP^JF01817

(Xu et al., 2023)

is ameliorated by ImpL2^HMC05809

(Chen et al., 2022)

is ameliorated by Stat92E^HMS00035

(Ding et al., 2021)

is ameliorated by dome^GD2612

(Ding et al., 2021)

is ameliorated by hop^HMS00761

(Ding et al., 2021)

is ameliorated by upd3^HMS00646

(Ding et al., 2021)

yki^JF03119

ameliorates Noonan syndrome

modeled by Hsap\RAF1^gof.UAS

(Yu et al., 2015)

yki^UAS.cUa

ameliorates peroxisome biogenesis disorder 2A

modeled by Pex5^GD14972

(Pinelli et al., 2024)

model of cancer

is ameliorated by Rox8^EY02351

(Guo et al., 2020)

yki^RNAi.UAS.cUa

ameliorates cancer

modeled by scrib^GD11666

(Ding et al., 2021)

exacerbates neurodegenerative disease

modeled by Zzzz\CAG^{127Q.UAS.Tag:HA}

(Dubey and Tapadia, 2018)

modeled by Hsap\HTT^Q93.ex1.UAS

(Dubey and Tapadia, 2018)

yki^{UAS.UTR.Tag:MYC}

model of cancer

is ameliorated by Rox8^EY02351

(Guo et al., 2020)

yki^{UAS.UTR-M2.Tag:MYC}

model of cancer

is ameliorated by Rox8^EY02351

(Guo et al., 2020)

yki^{3SA.lexAop.Tag:Myr(Unk),GFP}

model of cancer

is ameliorated by Akt^{ΔPH.UAS.Tag:Myr(Unk)}

(Chen et al., 2022)

is ameliorated by PGRP-SC2^UAS.cGa

(Chen et al., 2022)

is ameliorated by Rel^HMS00070

(Chen et al., 2022)

yki^{3SA.lexAop.sfGFP}

model of intestinal cancer

is ameliorated by Akt^{ΔPH.UAS.Tag:Myr(Unk)}

(Saavedra et al., 2023)

is ameliorated by REPTOR^NIG.13624R

(Saavedra et al., 2023)

is ameliorated by Pvr^HMS01662

(Xu et al., 2024)

Alleles Representing Disease-Implicated Variants

Genetic Tools, Stocks and Reagents

Sources of Stocks

Contact lab of origin for a reagent not available from a public stock center.

Bloomington Stock Center Disease Page

Related mammalian, viral, bacterial, or synthetic transgenes

Allele

Transgene

Publicly Available Stocks

Selected Drosophila transgenes

Allele

Transgene

Publicly Available Stocks

yki^3SA.UAS.cUa

P{UAS-yki.3SA.U}

yki^{UAS.UTR.Tag:MYC}

P{UAS-Myc-yki.UTR}

yki^{UAS.UTR-M1.Tag:MYC}

P{UAS-Myc-yki.UTR-M1}

yki^{UAS.UTR-M2.Tag:MYC}

P{UAS-Myc-yki.UTR-M2}

yki^{3SA.lexAop.Tag:V5}

P{lexAop-yki.3SA.V5}

yki^{3SA.lexAop.Tag:Myr(Unk),GFP}

P{lexAop-yki.3SA.MyrGFP}

yki^{3SA.lexAop.sfGFP}

P{lexAop-yki.S3A.sfGFP}

yki^UAS.cHa

P{UAS-yki}

w^*; P{UAS-yki}3/TM3, Sb¹

yki^{S168A.UAS.EGFP,Tag:HA}

P{UAS-yki.S168A.GFP.HA}

y¹ w^*; P{UAS-yki.S168A.GFP.HA}10-7-Y

yki^{UAS.cOa.Tag:V5}

P{UAS-yki.V5.O}

w^*; P{UAS-yki.V5.O}attP2

yki^{S168A.UAS.Tag:V5}

P{UAS-yki.S168A.V5}

w^*; P{UAS-yki.S168A.V5}attP2

yki^{S111A.S168A.S250A.UAS.Tag:V5}

P{UAS-yki.S111A.S168A.S250A.V5}

w^*; P{UAS-yki.S111A.S168A.S250A.V5}attP2

RNAi constructs available

Allele

Transgene

Publicly Available Stocks

yki^{RNAi.13xlexAop.cZa}

P{13xlexAop-yki.RNAi.Z}

yki^GD11187

P{GD11187}

w¹¹¹⁸; P{GD11187}v40497/TM3

y¹ v¹; P{TRiP.JF03119}attP2/TM3, Sb¹

y¹ v¹; P{TRiP.HMS00041}attP2

Selected Drosophila classical alleles

Allele

Allele class

Mutagen

Publicly Available Stocks

yki^AcidA

loss of function allele

CRISPR/Cas9

w^*; P{neoFRT}42D yki^AcidA/CyO, P{Dfd-EYFP.w^BmC}2

yki^B5

loss of function allele

l(2)gl⁴ yki^B5/CyO

References (29)

Report Sections

Open Close